Just days after seeing its badly battered stock price pick up on positive late-stage data from its fibromyalgia program, Jazz Pharmaceuticals told Reuters it's putting three of its programs on hold as it works out interest payments to bond holders. Jazz didn't make a fourth-quarter interest payment owed on $119 million in notes. "The interest issue has been the biggest overhang for our company and we continue to be in discussions with our senior secured note-holders to try to resolve that," Executive Director of Corporate Development Willie Quinn told Reuters. Report